Alan Palestine
Concepts (664)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uveitis | 64 | 2022 | 98 | 6.820 |
Why?
| Visual Acuity | 25 | 2021 | 248 | 2.370 |
Why?
| Eye Infections, Bacterial | 5 | 2020 | 27 | 2.170 |
Why?
| Retinopathy of Prematurity | 8 | 2020 | 102 | 2.170 |
Why?
| Endophthalmitis | 6 | 2020 | 27 | 2.120 |
Why?
| Vitrectomy | 8 | 2020 | 59 | 1.870 |
Why?
| Fluocinolone Acetonide | 2 | 2022 | 13 | 1.710 |
Why?
| Vitreous Body | 15 | 2022 | 103 | 1.490 |
Why?
| Fluorescein Angiography | 12 | 2021 | 88 | 1.390 |
Why?
| Macular Degeneration | 7 | 2022 | 125 | 1.340 |
Why?
| Glucocorticoids | 6 | 2022 | 554 | 1.320 |
Why?
| Cyclosporins | 31 | 1991 | 70 | 1.200 |
Why?
| Postoperative Complications | 7 | 2021 | 2190 | 1.200 |
Why?
| Ocular Hypertension | 3 | 2019 | 48 | 1.110 |
Why?
| Drug Costs | 2 | 2016 | 96 | 1.100 |
Why?
| Tomography, Optical Coherence | 4 | 2021 | 121 | 1.090 |
Why?
| Retinal Vessels | 6 | 2021 | 51 | 1.060 |
Why?
| Scleritis | 2 | 2022 | 11 | 1.030 |
Why?
| Cytomegalovirus Retinitis | 4 | 2016 | 15 | 1.020 |
Why?
| Diabetic Retinopathy | 2 | 2022 | 135 | 1.010 |
Why?
| Intraocular Pressure | 8 | 2020 | 252 | 1.000 |
Why?
| Uveitis, Posterior | 5 | 2019 | 11 | 0.990 |
Why?
| Anterior Chamber | 5 | 2021 | 19 | 0.980 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 552 | 0.970 |
Why?
| Retinal Detachment | 3 | 2020 | 47 | 0.970 |
Why?
| Eye Diseases | 10 | 2020 | 80 | 0.940 |
Why?
| Retinitis | 15 | 1993 | 17 | 0.940 |
Why?
| Corneal Ulcer | 1 | 2022 | 10 | 0.930 |
Why?
| Behcet Syndrome | 7 | 2021 | 14 | 0.930 |
Why?
| Retinal Diseases | 6 | 2020 | 70 | 0.890 |
Why?
| Corneal Transplantation | 4 | 2020 | 10 | 0.890 |
Why?
| Panuveitis | 1 | 2021 | 2 | 0.880 |
Why?
| Health Care Costs | 2 | 2016 | 412 | 0.880 |
Why?
| Acquired Immunodeficiency Syndrome | 22 | 1996 | 218 | 0.880 |
Why?
| Retinal Vasculitis | 1 | 2021 | 7 | 0.870 |
Why?
| Retrospective Studies | 27 | 2022 | 11727 | 0.850 |
Why?
| Eye Banks | 1 | 2020 | 7 | 0.840 |
Why?
| Inflammation | 8 | 2021 | 2458 | 0.820 |
Why?
| Granulomatosis with Polyangiitis | 1 | 2020 | 38 | 0.790 |
Why?
| MAP Kinase Kinase 1 | 1 | 2019 | 74 | 0.760 |
Why?
| Homosexuality, Male | 1 | 2020 | 169 | 0.750 |
Why?
| Humans | 157 | 2022 | 115152 | 0.730 |
Why?
| Methotrexate | 2 | 2016 | 240 | 0.710 |
Why?
| Practice Patterns, Physicians' | 3 | 2016 | 1242 | 0.690 |
Why?
| Surveys and Questionnaires | 8 | 2022 | 4769 | 0.690 |
Why?
| International Classification of Diseases | 1 | 2018 | 129 | 0.670 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 197 | 0.660 |
Why?
| Labor, Induced | 1 | 2017 | 31 | 0.650 |
Why?
| Fetal Membranes, Premature Rupture | 1 | 2017 | 37 | 0.650 |
Why?
| Labor, Obstetric | 1 | 2017 | 52 | 0.640 |
Why?
| Ophthalmologists | 1 | 2016 | 4 | 0.640 |
Why?
| Rheumatologists | 1 | 2016 | 6 | 0.640 |
Why?
| Retinal Drusen | 3 | 2021 | 26 | 0.630 |
Why?
| Cytomegalovirus | 2 | 2016 | 139 | 0.620 |
Why?
| Azathioprine | 1 | 2016 | 54 | 0.620 |
Why?
| Conjunctivitis | 2 | 2015 | 16 | 0.620 |
Why?
| Drug Implants | 5 | 2022 | 84 | 0.610 |
Why?
| Polychondritis, Relapsing | 1 | 2015 | 3 | 0.610 |
Why?
| Arthritis, Juvenile | 1 | 2016 | 37 | 0.600 |
Why?
| Autoimmune Diseases | 20 | 2009 | 410 | 0.600 |
Why?
| Ear Auricle | 1 | 2015 | 11 | 0.600 |
Why?
| Insurance, Health | 2 | 2016 | 263 | 0.590 |
Why?
| Vision Disorders | 2 | 2016 | 117 | 0.590 |
Why?
| Wet Macular Degeneration | 3 | 2020 | 24 | 0.580 |
Why?
| Surgical Wound Infection | 1 | 2018 | 224 | 0.570 |
Why?
| Geographic Atrophy | 3 | 2019 | 25 | 0.560 |
Why?
| Uveitis, Intermediate | 1 | 2014 | 1 | 0.560 |
Why?
| Needles | 1 | 2015 | 62 | 0.560 |
Why?
| Biopsy, Needle | 1 | 2015 | 195 | 0.550 |
Why?
| Neonatal Screening | 4 | 2018 | 183 | 0.540 |
Why?
| Diabetes Mellitus | 2 | 2022 | 948 | 0.530 |
Why?
| Adult | 70 | 2021 | 32204 | 0.530 |
Why?
| Premature Birth | 1 | 2017 | 236 | 0.530 |
Why?
| Female | 95 | 2022 | 63300 | 0.520 |
Why?
| DNA, Viral | 1 | 2016 | 436 | 0.520 |
Why?
| Complement Activation | 3 | 2022 | 342 | 0.500 |
Why?
| Male | 79 | 2022 | 60974 | 0.500 |
Why?
| Databases, Factual | 1 | 2018 | 1170 | 0.500 |
Why?
| Ophthalmology | 3 | 2022 | 56 | 0.500 |
Why?
| Middle Aged | 52 | 2021 | 28958 | 0.490 |
Why?
| Bacteria | 2 | 2018 | 661 | 0.490 |
Why?
| Cytomegalovirus Infections | 12 | 1999 | 180 | 0.490 |
Why?
| Gestational Age | 8 | 2020 | 764 | 0.490 |
Why?
| Aged | 37 | 2021 | 20309 | 0.480 |
Why?
| Vaccination | 1 | 2021 | 1094 | 0.480 |
Why?
| Skin Neoplasms | 2 | 2019 | 763 | 0.470 |
Why?
| Melanoma | 1 | 2019 | 718 | 0.470 |
Why?
| Placenta | 1 | 2018 | 591 | 0.470 |
Why?
| Follow-Up Studies | 12 | 2021 | 4959 | 0.460 |
Why?
| Electronic Health Records | 1 | 2018 | 694 | 0.460 |
Why?
| Sarcoidosis | 8 | 2021 | 118 | 0.450 |
Why?
| Antineoplastic Agents | 3 | 2020 | 2037 | 0.430 |
Why?
| Anti-Bacterial Agents | 2 | 2018 | 1377 | 0.420 |
Why?
| Macula Lutea | 3 | 2020 | 12 | 0.420 |
Why?
| Antiviral Agents | 10 | 2001 | 648 | 0.410 |
Why?
| Ciliary Body | 9 | 2018 | 34 | 0.410 |
Why?
| Complement Factor B | 2 | 2022 | 98 | 0.400 |
Why?
| Colorado | 9 | 2022 | 4496 | 0.390 |
Why?
| Practice Guidelines as Topic | 1 | 2018 | 1543 | 0.380 |
Why?
| Aqueous Humor | 4 | 2022 | 32 | 0.360 |
Why?
| Complement System Proteins | 3 | 2022 | 264 | 0.360 |
Why?
| Antigens | 14 | 1990 | 341 | 0.360 |
Why?
| Aged, 80 and over | 12 | 2021 | 6845 | 0.350 |
Why?
| Eye Proteins | 7 | 1990 | 71 | 0.340 |
Why?
| Conjunctival Diseases | 3 | 2017 | 17 | 0.340 |
Why?
| Retina | 18 | 1993 | 231 | 0.330 |
Why?
| Birth Weight | 4 | 2020 | 413 | 0.320 |
Why?
| Ganciclovir | 8 | 1999 | 47 | 0.320 |
Why?
| Uveitis, Anterior | 4 | 2018 | 9 | 0.320 |
Why?
| Corneal Diseases | 5 | 2017 | 37 | 0.310 |
Why?
| Incidence | 6 | 2021 | 2456 | 0.300 |
Why?
| Immunosuppressive Agents | 4 | 2016 | 679 | 0.300 |
Why?
| Opportunistic Infections | 4 | 1991 | 53 | 0.300 |
Why?
| United States | 10 | 2022 | 12598 | 0.290 |
Why?
| Fundus Oculi | 7 | 2021 | 37 | 0.290 |
Why?
| Bromocriptine | 4 | 1990 | 21 | 0.290 |
Why?
| Cross-Sectional Studies | 5 | 2022 | 4445 | 0.280 |
Why?
| Risk Factors | 10 | 2020 | 9105 | 0.270 |
Why?
| Laser Therapy | 5 | 2021 | 94 | 0.270 |
Why?
| Infant, Premature | 2 | 2019 | 454 | 0.270 |
Why?
| Specialization | 2 | 2016 | 127 | 0.270 |
Why?
| Retinal Vein Occlusion | 1 | 2004 | 12 | 0.270 |
Why?
| Time Factors | 12 | 2021 | 7041 | 0.260 |
Why?
| Fluoresceins | 5 | 1989 | 46 | 0.250 |
Why?
| Cohort Studies | 7 | 2020 | 5026 | 0.250 |
Why?
| Choroid | 11 | 2021 | 44 | 0.250 |
Why?
| Adolescent | 26 | 2020 | 18716 | 0.250 |
Why?
| Phacoemulsification | 3 | 2019 | 89 | 0.250 |
Why?
| Child | 20 | 2020 | 17939 | 0.250 |
Why?
| Registries | 3 | 2020 | 1919 | 0.250 |
Why?
| Infant | 8 | 2022 | 8124 | 0.250 |
Why?
| Infant, Very Low Birth Weight | 3 | 2018 | 69 | 0.240 |
Why?
| Algorithms | 4 | 2018 | 1519 | 0.240 |
Why?
| Foscarnet | 4 | 1996 | 22 | 0.240 |
Why?
| Young Adult | 6 | 2021 | 11032 | 0.240 |
Why?
| Anti-Inflammatory Agents | 3 | 2022 | 466 | 0.230 |
Why?
| Histocompatibility Antigens Class II | 9 | 1994 | 370 | 0.230 |
Why?
| Eye Neoplasms | 3 | 2017 | 14 | 0.230 |
Why?
| Chemokine CCL5 | 1 | 2022 | 50 | 0.230 |
Why?
| Albumins | 1 | 2022 | 102 | 0.220 |
Why?
| Posterior Capsulotomy | 1 | 2021 | 7 | 0.220 |
Why?
| Reference Standards | 2 | 2022 | 195 | 0.220 |
Why?
| Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.220 |
Why?
| Eye Infections, Viral | 2 | 1991 | 6 | 0.220 |
Why?
| Cataract | 3 | 2020 | 151 | 0.220 |
Why?
| Rats, Inbred Lew | 18 | 1994 | 108 | 0.220 |
Why?
| Anemia, Sickle Cell | 1 | 2004 | 183 | 0.220 |
Why?
| Antibodies, Monoclonal | 12 | 2020 | 1300 | 0.210 |
Why?
| Lasers, Solid-State | 1 | 2021 | 26 | 0.210 |
Why?
| AIDS-Related Opportunistic Infections | 2 | 1999 | 119 | 0.210 |
Why?
| National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.210 |
Why?
| Capsule Opacification | 1 | 2021 | 27 | 0.210 |
Why?
| Graft Rejection | 3 | 2021 | 591 | 0.210 |
Why?
| Laser Coagulation | 2 | 2018 | 48 | 0.210 |
Why?
| T-Lymphocytes, Helper-Inducer | 8 | 1994 | 132 | 0.210 |
Why?
| Retinal Pigment Epithelium | 1 | 2021 | 60 | 0.210 |
Why?
| Glaucoma, Angle-Closure | 1 | 2020 | 17 | 0.200 |
Why?
| Sensitivity and Specificity | 4 | 2018 | 1922 | 0.200 |
Why?
| Cataract Extraction | 3 | 2018 | 62 | 0.200 |
Why?
| Administration, Topical | 4 | 2016 | 156 | 0.200 |
Why?
| Infant, Newborn | 7 | 2020 | 5076 | 0.200 |
Why?
| Retinal Neovascularization | 1 | 2019 | 20 | 0.200 |
Why?
| Scleral Buckling | 1 | 2019 | 17 | 0.200 |
Why?
| Diagnostic Techniques, Ophthalmological | 2 | 2018 | 35 | 0.200 |
Why?
| Transplantation, Autologous | 1 | 2020 | 196 | 0.190 |
Why?
| Canada | 1 | 2020 | 325 | 0.190 |
Why?
| Endotoxins | 3 | 1991 | 265 | 0.190 |
Why?
| Complement Membrane Attack Complex | 1 | 2019 | 32 | 0.190 |
Why?
| Complement C3a | 1 | 2019 | 37 | 0.190 |
Why?
| Choroidal Neovascularization | 1 | 2019 | 37 | 0.190 |
Why?
| Pyrimidinones | 1 | 2019 | 94 | 0.190 |
Why?
| Biological Products | 1 | 2021 | 134 | 0.180 |
Why?
| Acyclovir | 5 | 2001 | 114 | 0.180 |
Why?
| Trabeculectomy | 1 | 2019 | 61 | 0.180 |
Why?
| Organ Transplantation | 1 | 2021 | 160 | 0.180 |
Why?
| Estrogen Replacement Therapy | 1 | 2019 | 129 | 0.180 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2021 | 184 | 0.180 |
Why?
| Computer Systems | 1 | 2018 | 53 | 0.180 |
Why?
| Immunity, Maternally-Acquired | 1 | 2018 | 24 | 0.180 |
Why?
| Antirheumatic Agents | 1 | 2021 | 254 | 0.180 |
Why?
| Treatment Outcome | 8 | 2021 | 9219 | 0.180 |
Why?
| Decision Making | 2 | 2016 | 799 | 0.170 |
Why?
| Intravitreal Injections | 1 | 2018 | 47 | 0.170 |
Why?
| Viral Load | 2 | 2016 | 443 | 0.170 |
Why?
| Organophosphonates | 1 | 1998 | 97 | 0.170 |
Why?
| Metformin | 1 | 2021 | 286 | 0.170 |
Why?
| Farber Lipogranulomatosis | 1 | 2017 | 4 | 0.170 |
Why?
| Disease-Free Survival | 1 | 2019 | 686 | 0.170 |
Why?
| Child, Preschool | 8 | 2020 | 9680 | 0.170 |
Why?
| Abnormalities, Multiple | 1 | 2019 | 171 | 0.170 |
Why?
| Reoperation | 1 | 2020 | 546 | 0.170 |
Why?
| Synovitis | 1 | 2017 | 22 | 0.170 |
Why?
| Amnion | 1 | 2017 | 27 | 0.160 |
Why?
| Risk | 4 | 2018 | 945 | 0.160 |
Why?
| Burnout, Professional | 1 | 2022 | 291 | 0.160 |
Why?
| Parity | 1 | 2017 | 102 | 0.160 |
Why?
| Arrestin | 13 | 1990 | 13 | 0.160 |
Why?
| Glaucoma | 1 | 2019 | 177 | 0.160 |
Why?
| Ophthalmoscopy | 1 | 2016 | 29 | 0.160 |
Why?
| Stevens-Johnson Syndrome | 1 | 2017 | 37 | 0.160 |
Why?
| Cicatrix | 1 | 2017 | 54 | 0.160 |
Why?
| Glaucoma, Open-Angle | 1 | 2018 | 82 | 0.160 |
Why?
| Medical Informatics | 1 | 2017 | 100 | 0.160 |
Why?
| Herpes Zoster | 2 | 2009 | 318 | 0.150 |
Why?
| Infant, Low Birth Weight | 1 | 2017 | 128 | 0.150 |
Why?
| Arthritis | 1 | 2017 | 108 | 0.150 |
Why?
| Terminology as Topic | 1 | 2017 | 202 | 0.150 |
Why?
| Polymerase Chain Reaction | 2 | 2016 | 1048 | 0.150 |
Why?
| Pregnancy | 2 | 2018 | 5316 | 0.150 |
Why?
| Transplantation, Homologous | 2 | 2016 | 471 | 0.150 |
Why?
| Macular Edema | 3 | 1991 | 25 | 0.150 |
Why?
| T-Lymphocytes | 12 | 2022 | 1807 | 0.150 |
Why?
| Lymphocytes | 9 | 1991 | 387 | 0.150 |
Why?
| Microbiological Techniques | 1 | 2015 | 32 | 0.150 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2017 | 155 | 0.140 |
Why?
| Recovery of Function | 1 | 2019 | 615 | 0.140 |
Why?
| Endoscopy | 1 | 2018 | 239 | 0.140 |
Why?
| Rheumatology | 1 | 2016 | 64 | 0.140 |
Why?
| Colony Count, Microbial | 1 | 2015 | 85 | 0.140 |
Why?
| Hematologic Neoplasms | 1 | 2016 | 114 | 0.140 |
Why?
| Weight Gain | 2 | 2016 | 496 | 0.140 |
Why?
| Insulin-Like Growth Factor I | 1 | 2017 | 283 | 0.140 |
Why?
| Disease Management | 1 | 2019 | 605 | 0.140 |
Why?
| Bronchopulmonary Dysplasia | 1 | 2019 | 308 | 0.140 |
Why?
| Phosphonoacetic Acid | 2 | 1991 | 10 | 0.140 |
Why?
| Physicians | 1 | 2022 | 734 | 0.130 |
Why?
| Chorioretinitis | 2 | 1992 | 2 | 0.130 |
Why?
| Lymphocyte Activation | 8 | 1990 | 1102 | 0.130 |
Why?
| Fetus | 1 | 2018 | 655 | 0.130 |
Why?
| Toxoplasmosis, Ocular | 2 | 1994 | 2 | 0.130 |
Why?
| Prospective Studies | 6 | 2020 | 6324 | 0.130 |
Why?
| Health Care Surveys | 1 | 2016 | 586 | 0.130 |
Why?
| Clinical Decision-Making | 1 | 2016 | 281 | 0.130 |
Why?
| Lymphoma, B-Cell | 2 | 1993 | 94 | 0.130 |
Why?
| Reproducibility of Results | 2 | 2018 | 2941 | 0.130 |
Why?
| Rats | 24 | 1994 | 6191 | 0.120 |
Why?
| Research Design | 1 | 2019 | 940 | 0.120 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 1992 | 85 | 0.120 |
Why?
| Protein Kinase Inhibitors | 1 | 2019 | 857 | 0.120 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 1998 | 991 | 0.120 |
Why?
| HIV-1 | 1 | 1998 | 790 | 0.120 |
Why?
| Kidney Diseases | 6 | 1989 | 402 | 0.120 |
Why?
| Iris | 3 | 1991 | 19 | 0.120 |
Why?
| HLA Antigens | 7 | 1991 | 213 | 0.120 |
Why?
| Creatinine | 7 | 1992 | 465 | 0.120 |
Why?
| Mothers | 1 | 2018 | 614 | 0.120 |
Why?
| Health Surveys | 1 | 2014 | 502 | 0.120 |
Why?
| Pars Planitis | 1 | 1992 | 1 | 0.120 |
Why?
| Patient Selection | 1 | 2016 | 707 | 0.110 |
Why?
| Retinal Necrosis Syndrome, Acute | 1 | 1991 | 10 | 0.110 |
Why?
| Risk Assessment | 2 | 2019 | 3215 | 0.110 |
Why?
| Injections, Intravenous | 7 | 1999 | 242 | 0.110 |
Why?
| Patient Care Team | 1 | 2016 | 532 | 0.110 |
Why?
| Cyclosporine | 1 | 1992 | 180 | 0.110 |
Why?
| Capillary Permeability | 2 | 1991 | 162 | 0.110 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1394 | 0.110 |
Why?
| Bacterial Infections | 3 | 1989 | 214 | 0.100 |
Why?
| HIV | 4 | 2020 | 210 | 0.100 |
Why?
| Clinical Competence | 1 | 2018 | 936 | 0.100 |
Why?
| Toxoplasma | 2 | 1994 | 31 | 0.100 |
Why?
| Cytophagaceae | 1 | 1990 | 1 | 0.100 |
Why?
| Capnocytophaga | 1 | 1990 | 2 | 0.100 |
Why?
| Antigens, Surface | 3 | 1989 | 165 | 0.100 |
Why?
| Antigens, Protozoan | 1 | 1989 | 18 | 0.100 |
Why?
| Urine | 1 | 1989 | 62 | 0.100 |
Why?
| Sebaceous Gland Neoplasms | 1 | 1989 | 3 | 0.090 |
Why?
| Eyelid Neoplasms | 1 | 1989 | 5 | 0.090 |
Why?
| Blood Chemical Analysis | 1 | 1989 | 105 | 0.090 |
Why?
| Odds Ratio | 4 | 2019 | 1063 | 0.090 |
Why?
| Drug Therapy, Combination | 5 | 1998 | 1007 | 0.090 |
Why?
| Tonometry, Ocular | 2 | 2019 | 91 | 0.090 |
Why?
| Animals | 34 | 2021 | 34758 | 0.090 |
Why?
| Eye | 7 | 1988 | 105 | 0.090 |
Why?
| Postoperative Period | 2 | 2019 | 314 | 0.080 |
Why?
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 1987 | 13 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 8 | 2019 | 887 | 0.080 |
Why?
| Antibody Formation | 3 | 1985 | 308 | 0.080 |
Why?
| Fanconi Syndrome | 1 | 1986 | 4 | 0.080 |
Why?
| Dextrans | 1 | 1987 | 81 | 0.080 |
Why?
| Autoantibodies | 6 | 1992 | 1234 | 0.080 |
Why?
| Escherichia coli | 1 | 1991 | 798 | 0.080 |
Why?
| Prednisolone | 2 | 2020 | 76 | 0.080 |
Why?
| Lymphocyte Transfusion | 1 | 1986 | 20 | 0.080 |
Why?
| Immunoenzyme Techniques | 8 | 1991 | 224 | 0.080 |
Why?
| Infliximab | 2 | 2021 | 90 | 0.080 |
Why?
| Interferometry | 1 | 1985 | 7 | 0.080 |
Why?
| Phenotype | 4 | 2022 | 2861 | 0.070 |
Why?
| Cell Movement | 2 | 1988 | 933 | 0.070 |
Why?
| Lasers | 2 | 1985 | 113 | 0.070 |
Why?
| Lenses, Intraocular | 2 | 2021 | 42 | 0.070 |
Why?
| Panophthalmitis | 1 | 1985 | 1 | 0.070 |
Why?
| Adrenal Cortex Hormones | 1 | 1989 | 521 | 0.070 |
Why?
| Uveomeningoencephalitic Syndrome | 3 | 1990 | 6 | 0.070 |
Why?
| Protein S Deficiency | 1 | 2004 | 7 | 0.070 |
Why?
| Choroiditis | 4 | 1991 | 6 | 0.070 |
Why?
| Myopia | 1 | 1984 | 34 | 0.070 |
Why?
| Biopsy | 5 | 1993 | 1050 | 0.070 |
Why?
| Tears | 4 | 1987 | 9 | 0.060 |
Why?
| Microscopy, Electron | 8 | 1988 | 446 | 0.060 |
Why?
| Phagocyte Bactericidal Dysfunction | 1 | 1983 | 12 | 0.060 |
Why?
| Ophthalmia, Sympathetic | 3 | 1990 | 3 | 0.060 |
Why?
| Retinal Artery | 2 | 1987 | 16 | 0.060 |
Why?
| Tretinoin | 1 | 1984 | 118 | 0.060 |
Why?
| Keratoplasty, Penetrating | 2 | 1994 | 5 | 0.060 |
Why?
| Immunologic Memory | 1 | 1985 | 305 | 0.060 |
Why?
| Complement Factor I | 1 | 2022 | 12 | 0.060 |
Why?
| Case-Control Studies | 2 | 2020 | 3261 | 0.060 |
Why?
| Adenocarcinoma | 1 | 1989 | 814 | 0.060 |
Why?
| Deltaretrovirus | 3 | 1986 | 12 | 0.060 |
Why?
| Aneurysm | 1 | 1982 | 25 | 0.060 |
Why?
| Cavernous Sinus | 1 | 1981 | 13 | 0.060 |
Why?
| Immunohistochemistry | 6 | 1993 | 1784 | 0.060 |
Why?
| 2-Aminopurine | 1 | 2001 | 10 | 0.060 |
Why?
| Herpes Zoster Ophthalmicus | 1 | 2001 | 5 | 0.050 |
Why?
| Arteriovenous Fistula | 1 | 1981 | 22 | 0.050 |
Why?
| Infusions, Intravenous | 2 | 2020 | 406 | 0.050 |
Why?
| Transplantation Tolerance | 1 | 2021 | 32 | 0.050 |
Why?
| Fibrinogen | 1 | 2022 | 155 | 0.050 |
Why?
| Abatacept | 1 | 2021 | 44 | 0.050 |
Why?
| Pigment Epithelium of Eye | 4 | 1990 | 34 | 0.050 |
Why?
| Adalimumab | 1 | 2021 | 41 | 0.050 |
Why?
| Tertiary Healthcare | 1 | 2020 | 26 | 0.050 |
Why?
| Biological Factors | 1 | 2021 | 38 | 0.050 |
Why?
| Biomarkers | 3 | 2021 | 3509 | 0.050 |
Why?
| Cyclopentolate | 1 | 2020 | 3 | 0.050 |
Why?
| Microscopy, Acoustic | 1 | 2020 | 10 | 0.050 |
Why?
| Gonioscopy | 1 | 2020 | 7 | 0.050 |
Why?
| Administration, Ophthalmic | 1 | 2020 | 14 | 0.050 |
Why?
| Sickness Impact Profile | 1 | 2020 | 66 | 0.050 |
Why?
| Kidney | 3 | 1989 | 1203 | 0.050 |
Why?
| Muscarinic Antagonists | 1 | 2020 | 30 | 0.050 |
Why?
| Amyloidosis | 1 | 2020 | 40 | 0.050 |
Why?
| Disease Models, Animal | 3 | 1991 | 3826 | 0.050 |
Why?
| Epithelium | 6 | 1991 | 302 | 0.050 |
Why?
| Carotid Arteries | 1 | 1981 | 187 | 0.050 |
Why?
| Immunologic Factors | 1 | 2022 | 230 | 0.050 |
Why?
| Protective Factors | 1 | 2019 | 96 | 0.050 |
Why?
| Immunization, Passive | 3 | 1988 | 86 | 0.050 |
Why?
| C-Reactive Protein | 1 | 2021 | 350 | 0.050 |
Why?
| Drug Combinations | 1 | 2020 | 304 | 0.050 |
Why?
| Cornea | 4 | 1989 | 103 | 0.050 |
Why?
| Anticoagulants | 1 | 2004 | 539 | 0.050 |
Why?
| Sarcoma, Kaposi | 4 | 1999 | 69 | 0.050 |
Why?
| Hypertension | 5 | 1991 | 1194 | 0.050 |
Why?
| Cytosine | 1 | 1998 | 49 | 0.050 |
Why?
| Trabecular Meshwork | 1 | 2019 | 76 | 0.050 |
Why?
| Prolactin | 2 | 1988 | 106 | 0.040 |
Why?
| Retinol-Binding Proteins | 2 | 1988 | 12 | 0.040 |
Why?
| Conjunctiva | 3 | 1989 | 51 | 0.040 |
Why?
| Organophosphorus Compounds | 1 | 1998 | 80 | 0.040 |
Why?
| CD4 Lymphocyte Count | 1 | 1998 | 290 | 0.040 |
Why?
| Academic Medical Centers | 1 | 2020 | 444 | 0.040 |
Why?
| Fluorometholone | 1 | 2017 | 4 | 0.040 |
Why?
| Logistic Models | 2 | 2019 | 2058 | 0.040 |
Why?
| Drug Evaluation | 2 | 1988 | 87 | 0.040 |
Why?
| Group Processes | 1 | 2017 | 60 | 0.040 |
Why?
| Nod2 Signaling Adaptor Protein | 1 | 2017 | 34 | 0.040 |
Why?
| North America | 1 | 2018 | 273 | 0.040 |
Why?
| Whole Exome Sequencing | 1 | 2017 | 85 | 0.040 |
Why?
| Chemotaxis, Leukocyte | 2 | 1987 | 140 | 0.040 |
Why?
| Administration, Oral | 3 | 1999 | 798 | 0.040 |
Why?
| HLA-DR Antigens | 5 | 1991 | 223 | 0.040 |
Why?
| Properdin | 1 | 1976 | 7 | 0.040 |
Why?
| Observer Variation | 1 | 2017 | 337 | 0.040 |
Why?
| Granuloma | 3 | 1987 | 85 | 0.040 |
Why?
| Sex Characteristics | 1 | 2022 | 686 | 0.040 |
Why?
| Cattle | 5 | 1991 | 969 | 0.040 |
Why?
| Infant, Extremely Low Birth Weight | 1 | 2016 | 14 | 0.040 |
Why?
| Interferon-gamma | 2 | 1991 | 770 | 0.040 |
Why?
| ROC Curve | 1 | 2018 | 494 | 0.040 |
Why?
| Plasma Cells | 2 | 1987 | 67 | 0.040 |
Why?
| Drug Resistance, Microbial | 1 | 1996 | 63 | 0.040 |
Why?
| Rats, Inbred Strains | 5 | 1987 | 494 | 0.040 |
Why?
| Magnesium | 2 | 1986 | 157 | 0.040 |
Why?
| Proteins | 2 | 2020 | 954 | 0.040 |
Why?
| Syndrome | 2 | 1987 | 342 | 0.040 |
Why?
| Chronic Disease | 4 | 1990 | 1650 | 0.040 |
Why?
| Intensive Care Units, Neonatal | 1 | 2017 | 163 | 0.040 |
Why?
| HIV Infections | 1 | 2009 | 2514 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2017 | 611 | 0.030 |
Why?
| Proteomics | 1 | 2020 | 775 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2019 | 1607 | 0.030 |
Why?
| Conjunctival Neoplasms | 2 | 1984 | 5 | 0.030 |
Why?
| Retinal Hemorrhage | 2 | 1986 | 21 | 0.030 |
Why?
| Recurrence | 2 | 1988 | 990 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 4 | 1988 | 2187 | 0.030 |
Why?
| Glycoproteins | 1 | 1976 | 337 | 0.030 |
Why?
| Blood Proteins | 2 | 1989 | 260 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 1988 | 1419 | 0.030 |
Why?
| Hypoglycemic Agents | 1 | 2021 | 1032 | 0.030 |
Why?
| Granulomatous Disease, Chronic | 2 | 1983 | 64 | 0.030 |
Why?
| Fluorescent Antibody Technique | 4 | 1989 | 429 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 7 | 1994 | 343 | 0.030 |
Why?
| Antibodies, Antinuclear | 2 | 1992 | 65 | 0.030 |
Why?
| Immunity, Cellular | 2 | 1985 | 303 | 0.030 |
Why?
| Immunization | 2 | 1985 | 411 | 0.030 |
Why?
| Dinoprostone | 2 | 1990 | 198 | 0.030 |
Why?
| Eye Infections | 1 | 1992 | 2 | 0.030 |
Why?
| Models, Biological | 2 | 2016 | 1812 | 0.030 |
Why?
| Sepsis | 2 | 1984 | 506 | 0.030 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 90 | 0.030 |
Why?
| Propionibacterium acnes | 1 | 1991 | 12 | 0.030 |
Why?
| Models, Statistical | 1 | 2016 | 676 | 0.030 |
Why?
| Epitopes | 3 | 1990 | 424 | 0.030 |
Why?
| Indomethacin | 2 | 1990 | 79 | 0.030 |
Why?
| Cells, Cultured | 5 | 1991 | 4291 | 0.030 |
Why?
| Cell Line | 5 | 1991 | 2930 | 0.030 |
Why?
| Biological Transport, Active | 1 | 1991 | 76 | 0.030 |
Why?
| Kinetics | 2 | 1988 | 1759 | 0.030 |
Why?
| Dogs | 2 | 1990 | 432 | 0.030 |
Why?
| Immunoglobulin lambda-Chains | 1 | 1990 | 6 | 0.030 |
Why?
| Transforming Growth Factor beta | 2 | 1991 | 463 | 0.030 |
Why?
| B-Lymphocytes | 2 | 1987 | 817 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2019 | 2853 | 0.030 |
Why?
| Coronary Circulation | 1 | 1991 | 163 | 0.030 |
Why?
| Microcirculation | 1 | 1991 | 168 | 0.030 |
Why?
| Random Allocation | 2 | 1988 | 396 | 0.030 |
Why?
| Multiple Sclerosis | 2 | 1985 | 334 | 0.030 |
Why?
| Endothelium, Corneal | 1 | 1990 | 11 | 0.030 |
Why?
| Cefazolin | 1 | 1990 | 17 | 0.020 |
Why?
| Fluorescein | 1 | 1989 | 23 | 0.020 |
Why?
| Protein Binding | 2 | 1989 | 2056 | 0.020 |
Why?
| Keratitis | 2 | 1994 | 12 | 0.020 |
Why?
| Quality of Life | 1 | 2020 | 2250 | 0.020 |
Why?
| Kidney Function Tests | 2 | 1989 | 159 | 0.020 |
Why?
| Diagnostic Errors | 1 | 1990 | 159 | 0.020 |
Why?
| Flow Cytometry | 2 | 1992 | 1167 | 0.020 |
Why?
| Recombinant Proteins | 2 | 1991 | 1422 | 0.020 |
Why?
| Retroviridae Proteins | 1 | 1989 | 11 | 0.020 |
Why?
| Mycophenolic Acid | 1 | 2009 | 81 | 0.020 |
Why?
| Osmolar Concentration | 1 | 1989 | 228 | 0.020 |
Why?
| Antimetabolites | 1 | 1989 | 28 | 0.020 |
Why?
| Hemocyanins | 2 | 1988 | 74 | 0.020 |
Why?
| Heptanoates | 1 | 1988 | 1 | 0.020 |
Why?
| Alkylating Agents | 1 | 1989 | 26 | 0.020 |
Why?
| Drug Eruptions | 1 | 1989 | 26 | 0.020 |
Why?
| Corneal Injuries | 1 | 1989 | 17 | 0.020 |
Why?
| Pneumonia, Pneumocystis | 1 | 1989 | 35 | 0.020 |
Why?
| Suramin | 1 | 1988 | 7 | 0.020 |
Why?
| Toxoplasmosis | 1 | 1989 | 28 | 0.020 |
Why?
| Interferon Type I | 1 | 1990 | 131 | 0.020 |
Why?
| Candidiasis | 1 | 1989 | 57 | 0.020 |
Why?
| Receptors, Virus | 1 | 1989 | 82 | 0.020 |
Why?
| HIV Envelope Protein gp120 | 1 | 1989 | 77 | 0.020 |
Why?
| Heptanoic Acids | 1 | 1988 | 69 | 0.020 |
Why?
| Lung Diseases | 2 | 1986 | 728 | 0.020 |
Why?
| Reverse Transcriptase Inhibitors | 1 | 1989 | 87 | 0.020 |
Why?
| Mycobacterium Infections | 1 | 1989 | 64 | 0.020 |
Why?
| Dexamethasone | 2 | 1987 | 310 | 0.020 |
Why?
| Central Nervous System Diseases | 1 | 1989 | 64 | 0.020 |
Why?
| Lens, Crystalline | 1 | 1990 | 124 | 0.020 |
Why?
| Placebos | 1 | 1988 | 212 | 0.020 |
Why?
| Antigen-Antibody Complex | 2 | 1985 | 93 | 0.020 |
Why?
| Injections | 1 | 1989 | 167 | 0.020 |
Why?
| Sugar Alcohol Dehydrogenases | 1 | 1987 | 7 | 0.020 |
Why?
| HIV Seropositivity | 1 | 1989 | 112 | 0.020 |
Why?
| Galactosemias | 1 | 1987 | 5 | 0.020 |
Why?
| Elapid Venoms | 1 | 1987 | 21 | 0.020 |
Why?
| Imidazolidines | 1 | 1987 | 19 | 0.020 |
Why?
| Colchicine | 1 | 1987 | 27 | 0.020 |
Why?
| Blood-Retinal Barrier | 1 | 1987 | 12 | 0.020 |
Why?
| Specific Gravity | 1 | 1987 | 13 | 0.020 |
Why?
| Receptors, Interleukin-2 | 1 | 1987 | 66 | 0.020 |
Why?
| Retinol-Binding Proteins, Plasma | 1 | 1987 | 5 | 0.020 |
Why?
| Community Health Services | 1 | 2009 | 213 | 0.020 |
Why?
| Prednisone | 2 | 1986 | 247 | 0.020 |
Why?
| Antigens, Differentiation | 1 | 1987 | 86 | 0.020 |
Why?
| Onchocerciasis | 1 | 1987 | 6 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 1990 | 1241 | 0.020 |
Why?
| Papilledema | 1 | 1987 | 33 | 0.020 |
Why?
| Drug Interactions | 1 | 1989 | 401 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 1990 | 498 | 0.020 |
Why?
| Aldehyde Reductase | 1 | 1987 | 106 | 0.020 |
Why?
| Herpesviridae Infections | 1 | 1989 | 171 | 0.020 |
Why?
| Molecular Weight | 1 | 1987 | 359 | 0.020 |
Why?
| Sclera | 1 | 1987 | 36 | 0.020 |
Why?
| Organ Specificity | 1 | 1987 | 299 | 0.020 |
Why?
| Down-Regulation | 1 | 1990 | 666 | 0.020 |
Why?
| Macaca mulatta | 1 | 1987 | 131 | 0.020 |
Why?
| Pituitary-Adrenal System | 1 | 1989 | 194 | 0.020 |
Why?
| Dihydroergotoxine | 1 | 1986 | 2 | 0.020 |
Why?
| Wound Healing | 1 | 1989 | 273 | 0.020 |
Why?
| Indium | 1 | 1986 | 9 | 0.020 |
Why?
| Heart Rate | 1 | 1991 | 839 | 0.020 |
Why?
| Receptors, Immunologic | 1 | 1987 | 207 | 0.020 |
Why?
| Peritoneal Cavity | 1 | 1986 | 30 | 0.020 |
Why?
| Osteoporosis | 1 | 1989 | 201 | 0.020 |
Why?
| Radioisotopes | 1 | 1986 | 40 | 0.020 |
Why?
| Hypothalamo-Hypophyseal System | 1 | 1989 | 270 | 0.020 |
Why?
| Muramidase | 1 | 1986 | 92 | 0.020 |
Why?
| Mutation | 1 | 2017 | 3403 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 1990 | 957 | 0.020 |
Why?
| Imidazoles | 1 | 1987 | 264 | 0.020 |
Why?
| Immune Tolerance | 1 | 1988 | 349 | 0.020 |
Why?
| Serum Albumin | 1 | 1986 | 161 | 0.020 |
Why?
| Double-Blind Method | 3 | 2001 | 1682 | 0.020 |
Why?
| Reference Values | 4 | 1989 | 854 | 0.020 |
Why?
| Connective Tissue | 1 | 1985 | 43 | 0.020 |
Why?
| Vascular Diseases | 1 | 1988 | 229 | 0.020 |
Why?
| Prognosis | 2 | 1985 | 3550 | 0.020 |
Why?
| Pigmentation Disorders | 1 | 1985 | 7 | 0.020 |
Why?
| Tetanus Toxoid | 1 | 1985 | 43 | 0.020 |
Why?
| Peptide Fragments | 1 | 1990 | 736 | 0.020 |
Why?
| Rabbits | 1 | 1986 | 795 | 0.020 |
Why?
| Acute Disease | 2 | 1987 | 995 | 0.020 |
Why?
| Fibrosis | 1 | 1987 | 414 | 0.020 |
Why?
| Retinitis Pigmentosa | 1 | 1984 | 15 | 0.020 |
Why?
| Lymphadenitis | 1 | 1984 | 4 | 0.020 |
Why?
| Kidney Tubules, Proximal | 1 | 1985 | 93 | 0.020 |
Why?
| Pemphigoid, Benign Mucous Membrane | 1 | 1984 | 4 | 0.020 |
Why?
| Blood Sedimentation | 1 | 1984 | 35 | 0.020 |
Why?
| Potassium | 1 | 1985 | 139 | 0.020 |
Why?
| Salmonella typhimurium | 1 | 1986 | 183 | 0.020 |
Why?
| Kidney Glomerulus | 1 | 1985 | 118 | 0.020 |
Why?
| Chlorides | 1 | 1985 | 132 | 0.020 |
Why?
| Tissue Distribution | 1 | 1985 | 365 | 0.020 |
Why?
| Referral and Consultation | 1 | 2009 | 652 | 0.020 |
Why?
| Oculomotor Muscles | 1 | 1984 | 37 | 0.020 |
Why?
| Isotretinoin | 1 | 1984 | 25 | 0.020 |
Why?
| Antibodies | 1 | 1987 | 417 | 0.020 |
Why?
| Longitudinal Studies | 1 | 1992 | 2676 | 0.020 |
Why?
| Optic Neuritis | 1 | 1984 | 29 | 0.020 |
Why?
| Acne Vulgaris | 1 | 1984 | 28 | 0.020 |
Why?
| Uveal Diseases | 1 | 1983 | 5 | 0.020 |
Why?
| Peptides | 1 | 1990 | 865 | 0.020 |
Why?
| Complement C3 | 1 | 1985 | 202 | 0.020 |
Why?
| Chediak-Higashi Syndrome | 1 | 1983 | 8 | 0.020 |
Why?
| Carbon Dioxide | 1 | 1985 | 236 | 0.020 |
Why?
| Liver Diseases | 1 | 1986 | 274 | 0.020 |
Why?
| Rats, Inbred BN | 2 | 1994 | 63 | 0.020 |
Why?
| Kidney Failure, Chronic | 1 | 1989 | 502 | 0.020 |
Why?
| Anemia | 1 | 1984 | 163 | 0.020 |
Why?
| Chemical and Drug Induced Liver Injury | 1 | 1984 | 138 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 1986 | 1217 | 0.010 |
Why?
| Fluorometry | 1 | 1981 | 23 | 0.010 |
Why?
| Immunochemistry | 3 | 1986 | 13 | 0.010 |
Why?
| Eyelid Diseases | 1 | 1981 | 11 | 0.010 |
Why?
| Melanosis | 1 | 1981 | 18 | 0.010 |
Why?
| Computers | 1 | 1981 | 70 | 0.010 |
Why?
| Histocytochemistry | 3 | 1986 | 99 | 0.010 |
Why?
| Liver | 1 | 1990 | 1844 | 0.010 |
Why?
| Edema | 1 | 1982 | 123 | 0.010 |
Why?
| Uric Acid | 1 | 1984 | 353 | 0.010 |
Why?
| Immunoglobulin G | 1 | 1985 | 802 | 0.010 |
Why?
| Confidence Intervals | 1 | 2001 | 339 | 0.010 |
Why?
| Calcium | 1 | 1986 | 1208 | 0.010 |
Why?
| T-Lymphocytes, Cytotoxic | 2 | 1994 | 175 | 0.010 |
Why?
| HLA-DQ Antigens | 2 | 1991 | 182 | 0.010 |
Why?
| Protease Inhibitors | 1 | 1999 | 116 | 0.010 |
Why?
| Arthus Reaction | 2 | 1987 | 9 | 0.010 |
Why?
| Permeability | 2 | 1987 | 160 | 0.010 |
Why?
| Sucrose | 2 | 1987 | 145 | 0.010 |
Why?
| Photoreceptor Cells | 2 | 1987 | 10 | 0.010 |
Why?
| Immunologic Techniques | 2 | 1986 | 43 | 0.010 |
Why?
| Macrophages | 2 | 1994 | 1325 | 0.010 |
Why?
| Survival Analysis | 1 | 1999 | 1410 | 0.010 |
Why?
| Transplantation, Isogeneic | 1 | 1994 | 18 | 0.010 |
Why?
| Tissue Donors | 2 | 1989 | 347 | 0.010 |
Why?
| Blotting, Southern | 1 | 1994 | 81 | 0.010 |
Why?
| DNA, Protozoan | 1 | 1994 | 28 | 0.010 |
Why?
| Shock, Septic | 1 | 1976 | 195 | 0.010 |
Why?
| Eye Enucleation | 1 | 1993 | 10 | 0.010 |
Why?
| Didanosine | 1 | 1993 | 15 | 0.010 |
Why?
| Viral Proteins | 2 | 1985 | 326 | 0.010 |
Why?
| Zidovudine | 1 | 1993 | 80 | 0.010 |
Why?
| Mice | 2 | 1986 | 15481 | 0.010 |
Why?
| Drug Tolerance | 1 | 1993 | 153 | 0.010 |
Why?
| Disease Progression | 1 | 1999 | 2494 | 0.010 |
Why?
| Cell Cycle | 1 | 1994 | 590 | 0.010 |
Why?
| HLA-DP Antigens | 1 | 1991 | 33 | 0.010 |
Why?
| Cyclophosphamide | 1 | 1991 | 233 | 0.010 |
Why?
| Neutrophils | 2 | 1987 | 1348 | 0.010 |
Why?
| Thromboxane A2 | 1 | 1990 | 14 | 0.010 |
Why?
| Histocompatibility Testing | 1 | 1990 | 124 | 0.010 |
Why?
| Biological Assay | 1 | 1991 | 117 | 0.010 |
Why?
| Immunophenotyping | 1 | 1991 | 297 | 0.010 |
Why?
| Leukotriene B4 | 1 | 1990 | 65 | 0.010 |
Why?
| Antigen-Presenting Cells | 1 | 1990 | 164 | 0.010 |
Why?
| Radioimmunoassay | 1 | 1990 | 180 | 0.010 |
Why?
| Aspartate Aminotransferases | 1 | 1990 | 100 | 0.010 |
Why?
| Alkaline Phosphatase | 1 | 1990 | 158 | 0.010 |
Why?
| Alanine Transaminase | 1 | 1990 | 154 | 0.010 |
Why?
| Immunoglobulins | 1 | 1990 | 141 | 0.010 |
Why?
| T-Lymphocyte Subsets | 1 | 1992 | 388 | 0.010 |
Why?
| Epoprostenol | 1 | 1990 | 133 | 0.010 |
Why?
| Coroners and Medical Examiners | 1 | 1989 | 10 | 0.010 |
Why?
| Virus Cultivation | 1 | 1989 | 30 | 0.010 |
Why?
| Lupus Erythematosus, Systemic | 1 | 1992 | 256 | 0.010 |
Why?
| Adrenal Cortex | 1 | 1988 | 35 | 0.010 |
Why?
| Chemical Fractionation | 1 | 1988 | 29 | 0.010 |
Why?
| Methods | 1 | 1988 | 80 | 0.010 |
Why?
| Arterioles | 1 | 1988 | 48 | 0.010 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 1988 | 87 | 0.010 |
Why?
| Metaraminol | 1 | 1987 | 1 | 0.010 |
Why?
| Survival Rate | 1 | 1993 | 1862 | 0.010 |
Why?
| Rats, Inbred WKY | 1 | 1987 | 47 | 0.010 |
Why?
| Peroxidases | 1 | 1987 | 26 | 0.010 |
Why?
| Rats, Inbred SHR | 1 | 1987 | 56 | 0.010 |
Why?
| Adrenal Gland Neoplasms | 1 | 1988 | 74 | 0.010 |
Why?
| Mannitol | 1 | 1987 | 40 | 0.010 |
Why?
| Cell Membrane Permeability | 1 | 1987 | 90 | 0.010 |
Why?
| Propionibacterium | 1 | 1986 | 2 | 0.010 |
Why?
| Edetic Acid | 1 | 1987 | 49 | 0.010 |
Why?
| AIDS-Related Complex | 1 | 1986 | 4 | 0.010 |
Why?
| HIV Antigens | 1 | 1987 | 19 | 0.010 |
Why?
| Leukocyte Count | 1 | 1988 | 328 | 0.010 |
Why?
| Serum Albumin, Bovine | 1 | 1987 | 71 | 0.010 |
Why?
| Mitosis | 1 | 1988 | 182 | 0.000 |
Why?
| Carcinoma | 1 | 1988 | 207 | 0.000 |
Why?
| Blood-Brain Barrier | 1 | 1987 | 114 | 0.000 |
Why?
| Argon | 1 | 1986 | 21 | 0.000 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 1986 | 52 | 0.000 |
Why?
| Tissue and Organ Procurement | 1 | 1989 | 211 | 0.000 |
Why?
| Homosexuality | 1 | 1986 | 17 | 0.000 |
Why?
| Agranulocytosis | 1 | 1986 | 33 | 0.000 |
Why?
| Antigens, Viral | 1 | 1987 | 189 | 0.000 |
Why?
| RNA-Directed DNA Polymerase | 1 | 1985 | 34 | 0.000 |
Why?
| Cell Division | 1 | 1988 | 858 | 0.000 |
Why?
| Regional Blood Flow | 1 | 1987 | 438 | 0.000 |
Why?
| Hydrogen Peroxide | 1 | 1987 | 306 | 0.000 |
Why?
| Light | 1 | 1988 | 365 | 0.000 |
Why?
| Pilot Projects | 1 | 1990 | 1426 | 0.000 |
Why?
| Drug Synergism | 1 | 1986 | 360 | 0.000 |
Why?
| Brain Neoplasms | 1 | 1993 | 983 | 0.000 |
Why?
| Interleukin-1 | 1 | 1990 | 1044 | 0.000 |
Why?
| Amino Acid Sequence | 1 | 1990 | 2161 | 0.000 |
Why?
| HLA-B27 Antigen | 1 | 1985 | 12 | 0.000 |
Why?
| Drug Evaluation, Preclinical | 1 | 1986 | 196 | 0.000 |
Why?
| Anterior Eye Segment | 1 | 1985 | 10 | 0.000 |
Why?
| Biomarkers, Tumor | 1 | 1992 | 1060 | 0.000 |
Why?
| Autoantigens | 1 | 1988 | 396 | 0.000 |
Why?
| Hyperemia | 1 | 1985 | 42 | 0.000 |
Why?
| Indians, North American | 1 | 1990 | 583 | 0.000 |
Why?
| DNA | 1 | 1992 | 1358 | 0.000 |
Why?
| Gram-Negative Bacteria | 1 | 1985 | 67 | 0.000 |
Why?
| Lymphokines | 1 | 1984 | 145 | 0.000 |
Why?
| Structure-Activity Relationship | 1 | 1986 | 553 | 0.000 |
Why?
| Molecular Sequence Data | 1 | 1990 | 3014 | 0.000 |
Why?
| Epithelial Cells | 1 | 1991 | 1016 | 0.000 |
Why?
| Ischemia | 1 | 1987 | 316 | 0.000 |
Why?
| Hodgkin Disease | 1 | 1986 | 117 | 0.000 |
Why?
| Cryptococcosis | 1 | 1984 | 23 | 0.000 |
Why?
| Monocytes | 1 | 1987 | 513 | 0.000 |
Why?
| Lymphatic Diseases | 1 | 1983 | 17 | 0.000 |
Why?
| Prevalence | 1 | 1990 | 2403 | 0.000 |
Why?
| alpha 1-Antitrypsin | 1 | 1985 | 117 | 0.000 |
Why?
| Clone Cells | 1 | 1984 | 253 | 0.000 |
Why?
| Colitis | 1 | 1986 | 214 | 0.000 |
Why?
| Meningitis | 1 | 1984 | 70 | 0.000 |
Why?
| Antibodies, Viral | 1 | 1986 | 543 | 0.000 |
Why?
| Kidney Transplantation | 1 | 1988 | 520 | 0.000 |
Why?
| Pain | 1 | 1988 | 780 | 0.000 |
Why?
| Microscopy, Fluorescence | 1 | 1984 | 434 | 0.000 |
Why?
| Biomechanical Phenomena | 1 | 1985 | 697 | 0.000 |
Why?
| Vasodilation | 1 | 1985 | 483 | 0.000 |
Why?
| Mice, Inbred BALB C | 1 | 1984 | 1316 | 0.000 |
Why?
| Clinical Trials as Topic | 1 | 1986 | 1005 | 0.000 |
Why?
| Endothelium, Vascular | 1 | 1988 | 964 | 0.000 |
Why?
| Killer Cells, Natural | 1 | 1983 | 332 | 0.000 |
Why?
| Blood Pressure | 1 | 1987 | 1728 | 0.000 |
Why?
| Pneumonia, Viral | 1 | 1986 | 353 | 0.000 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 1984 | 280 | 0.000 |
Why?
| Sexual Behavior | 1 | 1984 | 467 | 0.000 |
Why?
| Lung | 1 | 1985 | 3580 | 0.000 |
Why?
|
|
Palestine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|